EVFM (Evofem Biosciences) Total Assets: $7.44 Mil (As of Mar. 2026)


What is Evofem Biosciences Total Assets?

Evofem Biosciences EVFM -3.86% Total Assets is $7.44 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Evofem Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $7.44 Mil.

During the past 12 months, Evofem Biosciences's average Total Assets Growth Rate was -53.00% per year. During the past 3 years, the average Total Assets Growth Rate was -3.30% per year. During the past 5 years, the average Total Assets Growth Rate was -19.10% per year. During the past 10 years, the average Total Assets Growth Rate was 34.50% per year.

During the past 13 years, Evofem Biosciences's highest 3-Year average Total Assets Growth Rate was 181.40%. The lowest was -44.30%. And the median was 42.40%.

Total Assets is connected with ROA %. Evofem Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -157.74%. Total Assets is also linked to Revenue through Asset Turnover. Evofem Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.06.

Evofem Biosciences  (OTCPK:EVFM) Total Assets Explanation

Total Assets is connected with ROA %.

Evofem Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-21.86/( (20.274+7.442)/ 2 )
=-21.86/13.858
=-157.74 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Evofem Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.899/( (20.274+7.442)/ 2 )
=0.899/13.858
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Evofem Biosciences Total Assets Related Terms

Evofem Biosciences Total Assets Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Total Assets Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.51 25.16 10.55 23.79 20.27

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.88 14.38 13.81 20.27 7.44

Evofem Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Evofem Biosciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-74.336+94.61
=20.27

Evofem Biosciences's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=-77.63+85.072
=7.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $7.44 Mil mean?
Evofem Biosciences (EVFM) has a Total Assets of $7.44 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Evofem Biosciences and its competitors.
Is Evofem Biosciences' Total Assets too high?
Evofem Biosciences' current Total Assets is $7.44 Mil.
How does Evofem Biosciences' Total Assets compare to LYRA and CLSDQ?
Evofem Biosciences' Total Assets of $7.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Total Assets is $7.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 20.3% below its estimated fair value. The current Total Assets is $7.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Total Assets is $7.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.